drugset / Trial / NCT00755222

The Safety and Effectiveness of AA4500 in Subjects With Peyronie's Disease

NCT00755222

Phase 2 Completed 147 enrolled Endo USA Inc., a Keenova Therapeutics Company
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study evaluated the safety and effectiveness of AA4500 in improving the impact of Peyronie's disease on quality of life and improving penile curvature in men with Peyronie's disease

Timeline

Start
2008-08
Primary completion
2009-12
Completion
2009-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Collagenase Clostridium Histolyticum Protein / enzyme biologic Other

Indications